Evaluation of a New Screening Assay, Protein C Pathway (PCP) Test, for Identification of Defects in the Protein C Pathway

• References

• 1 Dahlbäck B, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C; predicition of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
• 2 Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant Protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82: 1989-93.
• 3 Kraus M, Noah M, Fickenscher K. The PCAT – a simple screening assay for assessing the functionality of the protein C anticoagulant pathway.. Thromb Res 1995; 79: 217-22
• 4 Robert E, Eschwege V, Hameg H, Drouet L, Aillaud MF.. Anticoagulant response to Agkistrodon contortrix venom (ACV) test: a new global test to screen for defects in the anticoagulant protein C pathway. Thromb Haemost 1996; 75: 562-5.
• 5 Preda L, Simioni P, Legnani C, Palareti G, Pogio M, Rossi E, Girolami A.. A new global test for the evaluation of the protein C-protein S system. Blood Coag Fibrinol 1996; 7 (04) 465-9.
• 6 Gable PS, Le DT, McGehee W, Rapaport SI.. A Protac-based screening test for activated protein C-resistant factor Va and other defects of the protein C anticoagulant pathway. Blood Coag Fibrinol 1997; 8 (06) 327-35.
• 7 Ruzicka K, Kapiotis S, Quehensberger P, Handler S, Pabinger-Fasching I, Mannhalter C, Jilma B, Speiser W.. Evaluation of new screening assay ProC Global for identification of defects in the protein C/protein S anticoagulant. Thromb Res 1997; 87: 501-10.
• 8 Rosen SB, Sturk A. Activated Protein C Resistance – A Major Risk Factor for Thrombosis.. Eur J Clin Chem Biochem 1997; 35 (07) 501-16.
• 9 Tripodi A, Negri B, Bertina RM, Mannucci PM. Screening for the FV:Q⁵⁰⁶ Mutation – Evaluation of Thirteen Plasma-based Methods for their Diagnostic Efficacy in Comparison with DNA Analysis.. Thromb Haemost 1997; 77 (03) 436-9.